Data shown is for informational purposes only and does not constitute investment advice. TopFund is not SEBI-registered. Consult a SEBI-registered advisor before investing.
Tata India Pharma & Healthcare Fund-Regular Plan-Growth
★★★★★ 3rd-party
External rating
- Source: Third-party data provider (Groww/CRISIL)
- Original rating: 2/5, displayed as-is — TopFund does not modify third-party ratings
- Refresh frequency: Whenever TopFund re-syncs this fund's data
- Limitations: The provider's own rating methodology isn't disclosed here — see the provider's own site for their criteria
TopFund Score: 66/100 · Good
How this score is calculated
- Star rating (35%)2/5
- 3Y CAGR (30%)19.59%
- Expense ratio (20%)1.1%
- AUM (15%)₹1,511 Cr
Not investment advice — an analytical read of public fund data. Methodology →
Tata Mutual Fund · Equity · Sectoral
₹38.7
AUM: ₹1,511 Cr
NAV updated 14 days ago
Plan
Regular
Option
Growth
Risk
Very High
Expense Ratio
1.1%
Exit Load
Exit load of 0.25% if redeemed within 30 days.
Fund Manager
Rupesh Patel, Sonam Udasi
Inception
Dec 2015
Benchmark
BSE Healthcare Total Return Index
Sharpe Ratio
0.0
Std Dev (1Y)
12.14%
Historical Returns (CAGR)
Annualized trailing returns computed from NAV history — past performance only, not a guarantee of future results.
1m
+2.72%
3m
-3.21%
6m
+7.44%
1y
+6.66%
3y
+19.59%
5y
+15.19%
10y
+15.61%
since inception
+11.49%
TopFund's Take on Tata India Pharma & Healthcare Fund-Regular Plan-Growth
Tata India Pharma & Healthcare Fund-Regular Plan-Growth holds up reasonably well within the Sectoral category, currently carrying a 2-star rating. TopFund's composite Health Score, which weighs rating, 3-year CAGR, expense ratio and fund size, puts it at 66/100.
Cost: At 1.1%, the expense ratio runs 10% above the Sectoral category average of 1.0%. That gap is worth weighing against the fund's actual performance versus cheaper peers before committing to a long SIP.
Risk-adjusted performance: Over the trailing 1-year period, the fund shows a negative Sharpe ratio of 0.0 — over the past year, returns haven't kept pace with the volatility involved, even before accounting for the risk-free rate. Separately, annualised volatility of 12.14% is fairly typical for Sectoral funds.
Who should invest: This fund is best suited to investors whose goals and risk appetite align with a Equity fund. Given the Very High risk rating, this fund is not suited to short-term goals or investors who may need to exit within 2-3 years.
This is an automated, data-driven analysis based on the fund's own metrics and its category peers — not personalized investment advice. Consult a SEBI-registered advisor before investing.
Sector Allocation
Asset Allocation
Fund Snapshot
Similar Funds
SBI Arbitrage Opportunities Fund - Direct Plan - Gr
SBI Mutual Fund
Franklin India Technology Fund-Growth
Franklin Templeton Mutual Fund
SBI HEALTHCARE OPPORTUNITIES FUND - DIRECT PLAN -GROWTH
SBI Mutual Fund
DSP Nifty Healthcare Index Fund - Direct- Growth
DSP Mutual Fund
Franklin India Technology Fund - Direct - Growth
Franklin Templeton Mutual Fund
BANK OF INDIA Manufacturing & Infrastructure Fund-Growth
Bank of India Mutual Fund
Tools & Guides for This Fund
Frequently Asked Questions about Tata India Pharma & Healthcare Fund-Regular Plan-Growth
The current NAV (Net Asset Value) of Tata India Pharma & Healthcare Fund-Regular Plan-Growth is ₹38.7. NAV is updated every business day after market close by AMFI.
1Y: 6.66% · 3Y CAGR: 19.59% · 5Y CAGR: 15.19%
The expense ratio of Tata India Pharma & Healthcare Fund-Regular Plan-Growth is 1.1% per annum. This is the annual fee charged by the fund to manage your investment.
Tata India Pharma & Healthcare Fund-Regular Plan-Growth is managed by Rupesh Patel, Sonam Udasi at Tata Mutual Fund.
Tata India Pharma & Healthcare Fund-Regular Plan-Growth is classified as a Very High risk fund. It is suitable for aggressive investors with a long-term horizon of 5+ years.
Tata India Pharma & Healthcare Fund-Regular Plan-Growth is a Sectoral fund. SIP suitability depends on your investment goal and risk profile.
You can start a SIP in Tata India Pharma & Healthcare Fund-Regular Plan-Growth with as little as ₹500 per month through most mutual fund platforms. The minimum lump sum investment is typically ₹1,000.
The Assets Under Management (AUM) of Tata India Pharma & Healthcare Fund-Regular Plan-Growth is ₹1,511 crore. AUM indicates the total market value of assets managed by the fund.
* Past performance is not indicative of future results. Mutual fund investments are subject to market risks.
Discussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
No comments yet — start the discussion.